Florida Attorney General sues Pfizer over alleged misleading vaccine ads

0 min read | Published on 01 Oct 2026, 09:32 PM |Updated on 01 Oct 2026, 09:32 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Florida Attorney General James Uthmeier filed a lawsuit against Pfizer
The complaint alleges misleading advertising of the COVID-19 vaccine
CEO Dr. Albert Bourla is named as a defendant in the suit

*this image is generated using AI for illustrative purposes only.

Pfizer faces a new legal challenge as Florida Attorney General James Uthmeier filed a lawsuit against the pharmaceutical giant and its CEO, Dr. Albert Bourla. The complaint alleges that the company engaged in misleading advertising regarding its COVID-19 vaccine.

The legal action targets both the corporate entity and its top executive. The Attorney General's office asserts that the marketing practices surrounding the vaccine were deceptive.

Legal Action Details

The lawsuit was formally filed by the Florida Attorney General's office. It specifically names:

Pfizer Inc.
Dr. Albert Bourla, Chief Executive Officer

The core allegation centers on claims that the advertising for the COVID-19 vaccine was misleading to consumers. No specific financial penalties or damages figures were disclosed in the initial filing summary.

Historical Stock Returns for Pfizer

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.55%	-1.31%	-11.66%	-21.25%	-26.60%	-31.39%

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might this lawsuit influence Pfizer's stock price volatility in the short term?

Could other state attorneys general follow Florida's lead with similar legal actions against pharmaceutical companies?

What impact could naming the CEO personally have on Pfizer's executive retention and corporate governance policies?

Pfizer

View Company Insights

View All News

Pfizer receives ₹1.26 crore income tax penalty for AY 2023-24

1 min read | Published on 29 Sept 2026, 01:34 PM |Updated on 29 Sept 2026, 01:34 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Pfizer Limited received a penalty of ₹1.26 crore from the Income Tax Transfer Pricing authority
The penalty relates to alleged non-furnishing of information during the AY 2023-24 audit
Company states the order has no material impact on financials and operations
Pfizer plans to appeal the order issued under Section 271G of the Income Tax Act

*this image is generated using AI for illustrative purposes only.

Pfizer Limited received an order levying a penalty of ₹1.26 crore from the Income Tax Transfer Pricing authority for Assessment Year 2023-24.

The order was issued by the Deputy or Additional Commissioner of Income Tax (Transfer Pricing) on September 25, 2026, and received by the company on September 28, 2026. The penalty was imposed under Section 271G of the Income Tax Act, 1961.

Reason for Penalty

The regulatory filing indicates that the penalty stems from alleged non-furnishing of specific granular information sought during the transfer pricing audit for AY 2023-24. The company has stated that it believes the order is not maintainable and is in the process of preferring an appeal against it.

Financial Impact

Pfizer asserted that the order has no material impact on its financial position, operations, or other activities. The company maintains strong grounds on merits regarding the assessment.

Particulars	Details
Authority	Deputy / Additional Commissioner of Income Tax (Transfer Pricing)
Penalty Amount	₹1.26 crore
Section	Section 271G of the Income Tax Act, 1961
Assessment Year	2023-24
Date of Order	September 25, 2026
Date of Receipt	September 28, 2026
Company Action	Appeal in process

Historical Stock Returns for Pfizer

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.55%	-1.31%	-11.66%	-21.25%	-26.60%	-31.39%

How might Pfizer's appeal strategy under Section 271G influence future transfer pricing compliance standards for multinational pharmaceutical companies in India?

Could this penalty signal a broader tightening of granular data disclosure requirements by Indian tax authorities for the upcoming assessment years?

What are the potential ripple effects on investor sentiment and stock valuation for Pfizer Limited if the appeal is delayed or unsuccessful?

Pfizer

View Company Insights

View All News